Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EBMT 2020 | Tocilizumab: CAR-T cell therapy in DLBCL

Matthew Frigault • 18 Aug 2020
EBMT 2020
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies CAR-T Tisagenlecleucel Tocilizumab
ELIANA

Matthew Frigault, MD, Massachusetts General Hospital, Boston, MA, discusses the use of tocilizumab after CAR-T cell therapy for the treatment of cytokine release syndrome (CRS) in refractory diffuse large B-Cell lymphoma (DLBCL) patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Matthew Frigault

Follow-up from a Phase I study of CART-ddBCMA for the treatment of R/R multiple myeloma 0:53
Follow-up from a Phase I study of CART-ddBCMA for the treatment of R/R multiple myeloma
Matthew Frigault • 10 Dec 2023
Itacitinib for the prevention of immune effector cell therapy–associated CRS 0:58
Itacitinib for the prevention of immune effector cell therapy–associated CRS
Matthew Frigault • 12 Dec 2023
Prophylaxis and management of CRS & ICANS
Bianca Santomasso et al. • 12 May 2023
Rapid CAR manufacture
Caron Jacobson et al. • 12 May 2023

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals